Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

NCT04044430 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Sponsor funding

Conditions

Metastatic Colon Adenocarcinoma
Metastatic Colorectal Adenocarcinoma
Metastatic Microsatellite Stable Colorectal Carcinoma
Metastatic Rectal Adenocarcinoma
Stage III Colon Cancer
Stage III Colorectal Cancer
Stage III Rectal Cancer
Stage IIIA Colon Cancer
Stage IIIA Colorectal Cancer
Stage IIIA Rectal Cancer
Stage IIIB Colon Cancer
Stage IIIB Colorectal Cancer
Stage IIIB Rectal Cancer
Stage IIIC Colon Cancer
Stage IIIC Colorectal Cancer
Stage IIIC Rectal Cancer
Stage IV Colon Cancer
Stage IV Colorectal Cancer
Stage IV Rectal Cancer
Stage IVA Colon Cancer
Stage IVA Colorectal Cancer
Stage IVA Rectal Cancer
Stage IVB Colon Cancer
Stage IVB Colorectal Cancer
Stage IVB Rectal Cancer
Stage IVC Colon Cancer
Stage IVC Colorectal Cancer
Stage IVC Rectal Cancer

Interventions

DRUG: Binimetinib
DRUG: Encorafenib
BIOLOGICAL: Nivolumab
OTHER: Questionnaire Administration

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]